Since exogenous and endogenous opioids are known to modulate immune function and opiate abuse is a major etiologic factor in human AIDS, there is reason to suspect that opiates themselves affect progression of AIDS. Evidence defining the role of opiates in progression of AIDS is less than clear, however, since there are various reasonable data to support any of three possible outcomes relative to opiate effects on AIDS progression. That is, no effects, exacerbatory effects, and protective effects. Data from our laboratory, using the best model of human AIDS, a monkey model, have, in fact, shown the potential of opiates to protect as well as exacerbate progression of AIDS. The most provocative aspect of these data was that none (0/6) of our SIV-infected opiate-dependent monkeys died over a 2-yr course of study, even though the expected death rate from AIDS was near to 1 in 2. Countering these seeming protective effects, however, was evidence that withdrawal of opiates, precipitated by naloxone, caused apparent SIV induction and prominent immune disturbance, that could be regarded as exacerbatory forces in the progression of AIDS. We also found that 2/6 monkeys developed iatrogenically induced opportunistic bacterial dermatitis near the end of this study, at the site of repeated opiate injections. These findings led us to hypothesize that the effects of opiates on progression of AIDS are conditionally dependent on the stability of opiate dependency, virulence of the AIDS virus, and the nature of secondary opportunistic infections. Unfortunately, the fact that this monkey study was only a pilot study meant that firm conclusions from these findings are unwarranted. The present proposal, therefore, is aimed at validating the main findings of our previous pilot study: protection against AIDS progression, induction of SIV upon opiate withdrawal; and, potential depression of anti-bacterial phagocytic capacity. This task is to be done in a statistically meaningful way that will not compromise animal welfare. These studies should improve understanding of the role of opiates in AIDS.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA010440-05
Application #
6350496
Study Section
Human Development Research Subcommittee (NIDA)
Program Officer
Sharp, Charles
Project Start
1997-02-10
Project End
2002-03-31
Budget Start
2001-02-10
Budget End
2002-03-31
Support Year
5
Fiscal Year
2001
Total Cost
$558,366
Indirect Cost
Name
Emory University
Department
Psychiatry
Type
Schools of Medicine
DUNS #
042250712
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Wiederin, Jayme L; Yu, Fang; Donahoe, Robert M et al. (2012) Changes in the plasma proteome follows chronic opiate administration in simian immunodeficiency virus infected rhesus macaques. Drug Alcohol Depend 120:105-12
Cloak, Christine C; Chang, Linda; O'Neil, Shawn P et al. (2011) Neurometabolite abnormalities in simian immunodeficiency virus-infected macaques with chronic morphine administration. J Neuroimmune Pharmacol 6:371-80
Donahoe, Robert M; O'neil, Shawn P; Marsteller, Frederick A et al. (2009) Probable deceleration of progression of Simian AIDS affected by opiate dependency: studies with a rhesus macaque/SIVsmm9 model. J Acquir Immune Defic Syndr 50:241-9
Yearley, Jennifer H; Kanagy, Sarah; Anderson, Daniel C et al. (2008) Tissue-specific reduction in DC-SIGN expression correlates with progression of pathogenic simian immunodeficiency virus infection. Dev Comp Immunol 32:1510-21
Donahoe, Robert M (2004) Multiple ways that drug abuse might influence AIDS progression: clues from a monkey model. J Neuroimmunol 147:28-32
Madden, John J; Wang, Yichong; Lankford-Turner, Pamela et al. (2002) Does reduced DNA repair capacity play a role in HIV infection and progression in the lymphocytes of opiate addicts? J Acquir Immune Defic Syndr 31 Suppl 2:S78-83